Research Article

Multilayer UiO-66-NH₂@CS/HA-PNIPAM Nanocomposite for Dual-Responsive Dexamethasone Delivery and Anti-Inflammatory Activity

Authors

  • Zahra Joorbonyan * Morvarid Intelligent Industrial Systems Research Group, Iran.
  • Seyedeh Tahereh Mirhadian Morvarid Intelligent Industrial Systems Research Group, Iran.

https://doi.org/10.48313/bic.vi.85

Abstract

Dexamethasone (DEX) is an effective anti-inflammatory drug; however, its therapeutic application can be limited by rapid drug diffusion and insufficient control over the local release profile. In this study, a multifunctional DEX-loaded UiO-66-NH₂@chitosan/hyaluronic acid–poly(N-isopropylacrylamide) (UiO-66-NH₂@CS/HA-PNIPAM) nanocomposite was developed as a dual pH/temperature-responsive drug delivery platform. DEX was incorporated into porous UiO-66-NH₂ nanoparticles, followed by sequential coating with Chitosan (CS)/Hyaluronic Acid (HA) and a thermoresponsive PNIPAM layer. The physicochemical properties, drug encapsulation, swelling behavior, temperature responsiveness, in vitro release, stability, cytocompatibility, and anti-inflammatory activity of the formulations were evaluated. The final F4 formulation exhibited an Encapsulation Efficiency (EE%) of 86.7±2.0% and a particle size of 251.8±9.1 nm, with a Polydispersity Index (PDI) of 0.26±0.03. F4 showed pronounced pH-dependent swelling, increasing from 48.7±3.5% at pH 5.5 to 82.6±4.8% at pH 7.4, while its particle size decreased from 251.8±9.1 nm at 25°C to 211.4±7.1 nm at 37°C, demonstrating temperature-responsive behavior. At pH 7.4 and 37°C, the 24-h cumulative DEX release from F4 was 43.5±2.1%, compared with 78.4±3.1% for the uncoated formulation. The nanocomposite-maintained cell viability above 90% at concentrations up to 100 μg/mL. In an LPS-induced inflammatory model, F4 reduced TNF-α and IL-6 concentrations to 108.6±7.5 and 82.3±6.9 pg/mL, respectively, compared with 286.7±14.8 and 238.5±12.6 pg/mL for the LPS control. The developed UiO-66-NH₂@CS/HA-PNIPAM nanocomposite provided controlled DEX release together with pH/temperature-responsive behavior, acceptable cytocompatibility, and enhanced anti-inflammatory activity, supporting its potential as a multifunctional platform for controlled anti-inflammatory drug delivery.

Keywords

Dexamethasone Chitosan Hyaluronic acid PNIPAM Drug delivery Controlled release Anti-inflammatory activity
References (30)
  1. [1] Johnson, D. B., Lopez, M. J., & Kelley, B. (2023). Dexamethasone. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK482130/

  2. [2] Waldron, N. H., Jones, C. A., Gan, T. J., Allen, T. K., & Habib, A. (2013). Impact of perioperative dexamethasone on postoperative analgesia and side-effects: Systematic review and meta-analysis. British Journal of Anaesthesia, 110(2), 191–200. https://doi.org/10.1093/bja/aes431

  3. [3] Ahmed, M. H., & Hassan, A. (2020). Dexamethasone for the treatment of coronavirus disease (COVID-19): A review. SN Comprehensive Clinical Medicine, 2(12), 2637–2646. https://doi.org/10.1007/s42399-020-00610-8

  4. [4] Corcoran, T. B., Myles, P. S., Forbes, A. B., Cheng, A. C., Bach, L. A., O’Loughlin, E., ... & Ho, K. M. (2021). Dexamethasone and surgical-site infection. New England Journal of Medicine, 384(18), 1731-1741. https://doi.org/10.1056/NEJMoa2028982

  5. [5] Horby, P., Lim, W. S., Emberson, J., Mafham, M., Bell, J., Linsell, L., ... & Recovery Collaborative Group. (2020). Effect of dexamethasone in hospitalized patients with COVID-19–preliminary report. MedRxiv, 2020-06. https://doi.org/10.1101/2020.06.22.20137273

Article Metrics

How to Cite

Joorbonyan, Z., & Mirhadian, S. T. . (2026). Multilayer UiO-66-NH₂@CS/HA-PNIPAM Nanocomposite for Dual-Responsive Dexamethasone Delivery and Anti-Inflammatory Activity. Biocompounds, 3(4), 314-333. https://doi.org/10.48313/bic.vi.85

Similar Articles

1-10 of 48

You may also start an advanced similarity search for this article.